This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk05: Hello, and welcome to the Catalyst Pharmaceuticals third quarter 2023 financial results conference call and webcast. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. You may be placed into question queue at any time by pressing star one on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Chief Financial Officer Ali Grande. Please go ahead, Ali.
spk01: Good morning, everyone, and thank you for joining our conference call to discuss Catalyst's third quarter 2023 financial results and corporate highlights. Leading the call today is Patrick McEnany, Chairman and Chief Executive Officer. We are also joined on today's call by Dr. Stephen Miller, our Chief Operating Officer and Chief Scientific Officer, and Jeffrey Del Carmen, our Chief Commercial Officer. Before we begin, I would like to remind you that in our remarks this morning and in the Q&A session, we will make statements about expected future results, which may be forward-looking statements for purposes of federal securities laws. These statements relate to our current expectations, estimates, and projections and are not guarantees of future performance. They involve risks, uncertainties, and assumptions that are difficult to predict and may prove not to be accurate. Actual results may vary from the expectations contained in our forward-looking statements. These forward-looking statements should be considered only in conjunction with the detailed information contained in our SEC filings, including the risk factors described in our 2022 Annual Report on Form 10-K. At this time, I'll turn the call over to Pat.
spk04: Thanks, Sally. Good morning, and welcome, everyone, to our third quarter 2023 Financial Results Conference call. We are pleased to report another quarter marked by exceptional financial results and the completion of another significant acquisition further shaping the future of the company. First, I'd like to review key financial highlights from the third quarter of 2023. We achieved total product revenues of $102.6 million, representing a year-over-year increase of 79.5% driven by continued revenue growth for our FirdApps and FICOMPA franchises. We reported yet another new all-time high net revenue of FirdApps for $66.2 million, reflecting an increase of 15.8% year-over-year, and year-to-date through the third quarter, FirdApps revenues increased by 23.1%, over the same period last year. This strong performance underscores another quarter of outstanding organic growth for FredEPS. Our overall revenue performance was fortified by PICOMPA net product revenues of $36.4 million, establishing a favorable 5.3% third quarter increase compared to the second quarter of this year. underscoring an important contribution to our growing revenue base. This should serve as a testament to our exceptional execution across all business fronts and our ability to successfully integrate the acquisition of strategic products. As a result of our year-to-date progress, we are raising our 2023 total revenue guidance to between $390 million and $395 million, from our previous guidance of $380 to $390 million. Non-GAAP net income for the third quarter was $55.9 million, or 49 cents per share diluted. This excludes from GAAP net income, non-cash, stock-based compensation, depreciation, a non-recurring one-time in-process R&D expense of $81.5 million associated with the acquisition of the North American license for a GAMRI, better known, also chemically known as Remora Loan, and the amortization of intangible assets. GAAP net loss was $30.8 million, or 29 cents per diluted share, which again includes the non-recurring one-time expense of $81.5 million associated with the acquisition of the Egamery license. While these previously disclosed non-recurring in-process R&D expenses impacted on our overall GAAP earnings per share, our performance underscores our fiscal discipline and operational execution. We ended the quarter with cash or cash equivalents of $121 million and continue to have no funded debt on our balance sheet. Allie will provide you with more financial details during her presentation. Our recent acquisitions reinforce our confidence that we are on the right path towards realizing our near and longer term strategic and financial goals. Early in the third quarter, we acquired from Santera Pharmaceuticals the license for the North American rights tube from Oralone, again, brand name Agamri, which was pending an FDA approval for the treatment of Duchenne muscular dystrophy, or DMD. On October 26th of this year, we announced the FDA approval of Agamri, oral solution, a novel corticosteroid for the treatment of DMD. We believe that Agamri may offer the potential to increase the duration of ambulation and mobility in these patients, thereby significantly improving their overall quality of life, also providing a more favorable side effect profile compared to other traditional steroid treatments. Steve will have more to say about the Agamri approval and the potential benefits to DMD patients during his presentation. As most of you know, the current standard of care treatment for DMD involves corticosteroids, which often come with significant side effects. It is estimated that between 11,000 and 13,000 children in the U.S. are affected by DMD, with approximately 70% of the patients currently receiving corticosteroid treatment. We strongly believe that a gamma-rate has the transformational potential to reshape the treatment period for this debilitating rare disease and holds the prospect for future possibilities for other chronic inflammatory conditions. Agamri has orphan drug and rare pediatric disease designations status for DMD, qualifying it for seven years of U.S. market exclusivity, as well as a number of issued and pending patents that extend to 2040. Per our licensing agreement with Santera, the approval of the GAMRI triggers a $36 million milestone payment that, when paid this fourth quarter of this year, will be recorded as an intangible asset and amortized over its useful life of 10.5 years. We are excited about the commercial launch of the GAMRI. a highly synergistic product to our existing neuromuscular franchise, which is planned to occur in the first quarter of 2024. At that time, we will introduce our comprehensive financial assistance program aimed at helping to ensure access and affordability for all DMD patients through our white glove Catalyst Pathways platform. Jeff will address some of the questions that many of you are asking about the opportunity that Agamri represents for Catalyst. You will note in the fourth quarter, we anticipate incurring an additional $6 to $7 million in commercial and other expenses related to the Agamri launch preparations. In the third quarter, We announced that the SNDA seeking to increase the daily maximum dose of Ferdaps to 100 milligrams had been accepted for filing. We have been provided a PDUFA action date of June 4, 2024. This represents a meaningful milestone as we estimate that about 40% of patients currently on treatment are already at or approaching the current maximum daily dose of 80 milligrams. We also just recently announced the allowance of two new patents to further strengthen the Ferdapps intellectual property estate, which currently has patent protection until 2037. Plans are underway to list these patents in the FDA's Orange Book as soon as they are issued, bringing the total number of listed patents of Ferdapps to eight. With the second consecutive full quarter of FICOMPA under our belt, We are pleased with its positive growth trend. We attribute this success to our dedicated epilepsy franchise teams, who are actively engaged with healthcare providers in the efficacy communities. We expect a continued tailwind for Phi Kappa due to its unique status as the only non-competitive AMPA receptor antagonist, and that epilepsy patients tend to stay with the current treatment regimen once they achieve seizure-free status. As we enter the fourth quarter, we expect an NDA submission for FredApps to the PMDA in Japan by our partner, Dido Pharma, before the end of this year, which will trigger a $2 million regulatory milestone payment by Dido to Catalyst. Acceptance of the submission in Japan also triggers an expansion of our territorial rights for FRDAPs under our amended license agreement with CERB. We are developing plans to pursue opportunities to expand our global footprint through strategic partnerships with our current focus on the Asia Pacific and LATAM regions. Looking at the business development side of the company, where we are focused on pursuing adequately de-risked and value-added transaction opportunities. We continue to demonstrate progress with the recent closing of the acquisition of the North American rights to a GAMRI from Santera. We've advanced our portfolio expansion strategy search and evaluation efforts around two key pillars. focusing on broadening and diversifying our rare neuromuscular and epilepsy product portfolios with sufficiently de-risked innovative therapies that address critical unmet medical needs. And second, expanding the geographic footprint of our existing products. Overall during this quarter, we've gained significant ground in our portfolio expansion efforts. We are currently in the advanced stages of due diligence on additional commercial stage opportunities that could come to fruition over the next few quarters. After a robust and comprehensive search, I was very pleased to announce that Rich Daley was our candidate of choice as my successor as CEO. As reported, Rich has over three decades of biopharma experience with large multinationals as well as smaller, more entrepreneurial companies. Rich's background and core strength is on the commercial side of the business, an attribute that is key to our near-term and mid-term strategic plan. He has been on our board of directors for almost nine years and has been an integral part of the team that has helped design our current strategic plan and focus. Rich and I have been working together closely since the announcement to ensure a smooth transition come January 1st of next year. Looking ahead to next year, we are fully prepared for sustained progress fueled by our ability to execute, paving the path for further growth. With the collective capabilities of our Catalyst team, there is no doubt that we will continue to achieve noteworthy accomplishments and making a lasting impact on the lives of the patients that we serve. I'll now turn the call over to Jeff DelCarmen, our Chief Commercial Officer, who will update us on our commercial activities.
spk06: Thanks, Pat, and good morning, everyone. In the last quarter, our commercial team has achieved outstanding results across the board. I would like to draw your attention to our exceptional performance in this record-breaking quarter in our continuous strategic efforts which are paving the way for future successes. We are delighted to report Q3 combined net revenues of $102.6 million, showcasing a substantial year-over-year growth of 79.4%. This remarkable performance was fueled by BirdApps reaching an all-time high of $66.2 million and the consistent strong contribution from FICOMPA, which generated $36.4 million. Catalyst is strategically positioned to meet the revised revenue guidance range of $390 million to $395 million. First, let's discuss our progress with Ferdaps, which has emerged as a pivotal therapeutic option for individuals in the U.S. who are affected by Lambert-Eaton Myasthenic Syndrome, or LENS. Q3 net revenues of $66.2 million represents a year-over-year increase of 15.8% versus the third quarter last year. In year-to-date through the third quarter, Ferdap's revenues increased by 23.1% over the same period last year, a direct result of steady new patient starts and an annual discontinuation rate trending below 20%. Net new patients in Q3 were the highest quarterly total this year. Prescription approval rates exceeded 90% for all types of payers, including government and private commercial insurers. Patients enrolled in Catalyst Pathways, including those with Medicare coverage and accessing Foundation assistance, experienced an average monthly copay of less than $2. We have a strong belief in FERDAPS's long-term organic growth prospects. First, we have a robust pipeline with over 500 patient leads diagnosed with LEMS who have not yet started FERDAPS treatment. Additionally, we have identified new sources for potential LEMS patients, ensuring a continuous influx of high-quality leads in the foreseeable future. We recently presented an abstract at the World Conference on Lung Cancer in September that estimated the LEMS prevalence in the United States could be as large as 5,600 individuals, a significant increase from the previously estimated prevalence of 3,000. This estimate is derived from a detailed real-world data analysis specifically focusing on the prevalence of LEMS diagnosis among patients with small cell lung cancer. Currently, we assess that greater than 80% of small cell lung cancer LEMS patients are undiagnosed, representing a significant opportunity for growth. In the last year, our LEMS education initiatives have demonstrated their effectiveness. This is evident from the notable rise in voltage-gated calcium channel antibody tests, which streamline the diagnostic process for LEMS patients and consequently expand the pool of eligible candidates for FERDAPS treatment. Furthermore, our targeted educational campaigns aimed at thoracic oncologists have successfully contributed to the identification of a higher number of diagnosed small cell lung cancer LEMS patients. Additionally, FDA approval of the company's SNDA, to increase the indicated maximum daily dose of FRDFs from 80 to 100 milligrams, may offer significant benefits to some patients. As Pat mentioned earlier, we anticipate that it could provide a notable improvement in the daily dosage of FRDFs for a significant portion of our patient population. Now I would like to provide some highlights of our progress with Vicompa. FICOMPA commercialization is surpassing our expectations. We have actively collaborated with healthcare providers, expanding our outreach and forming valuable relationships that have significantly contributed to FICOMPA's success. In Q3, FICOMPA achieved net revenues of $36.4 million, marking a 5.2% increase quarter over quarter. We are fostering crucial partnerships with patient advocacy groups to enhance awareness and promote our mission. Let's turn to Agamri, a promising novel anti-inflammatory corticosteroid that addresses a significant unmet need for more tolerable steroids for patients living with Duchenne muscular dystrophy, or DMD. The US prevalence for DMD is estimated to be between 11,000 and 13,000 patients Of patients currently being treated for DMD, approximately 70% of these patients receive concomitant steroid treatment. However, steroid treatment is associated with significant side effects. We believe that a GAMRI will offer an advancement to the current treatment paradigm, addressing an important unmet need for DMD patients and caregivers. As we have disclosed before, we expect a commercial launch in the first quarter 2024. We will integrate Agamri into our neuromuscular franchise where we can leverage the team's demonstrated capabilities, commercial expertise, and experience. We are in the final stages of hiring 10 commercial personnel to support the pending launch, mostly in marketing and patient services. Our existing neuromuscular sales force of 16 regional account managers and two area business directors will have responsibility for both Ferdaps and Agamri. In addition, Agamri will be supported by our best-in-class Catalyst Pathways program to help ensure that all eligible patients can access the product. Catalyst intends to price Agamri responsibly to ensure access for all appropriate patients living with DMD. We have done considerable outreach to key stakeholders since the acquisition was completed in July. Santera had conducted one round of market and pricing research for Agamri, which was refreshed by Catalyst in October of this year. In addition, we've had several meetings with DMD community members and key advocates where we received feedback regarding pricing and access. Lastly, Catalyst held an advisory board meeting with approximately 10 key opinion leaders in October. Based on the feedback from our constituents and analysis of the DMD market, the wholesale acquisition cost of a gamary will be at a slight discount to Enflaza. We will implement the same financial programs as we have for Ferdaps to ensure the average patient out-of-pocket cost will be less than $2 per month. More details on the commercial launch will be available in the coming months. In summary, we are extremely satisfied with our performance in Q3 and remain highly confident in achieving our adjusted 2023 revenue forecast of 390 million to 395 million. Furthermore, as we gear up for the launch of Agamri, We will capitalize on our proven commercial expertise. I extend my heartfelt gratitude to the entire team at Catalyst for their dedicated commitment to patients, and I am eagerly anticipating a successful Q4 ahead. I will now turn the call over to Dr. Stephen Miller, our Chief Operating Officer and Chief Scientific Officer, for an update on R&D activities.
spk02: Thank you, Jeff. Our clinical development and regulatory strategy for Ferdaps continues to focus on expanding access to all LEMS patients, enhancing the Ferdaps patented state to maximize its commercial potential, and integrating the newly acquired Ficampa and Agamri products into catalyst organization and then optimizing the commercial potential of those new assets. First, I would like to discuss our development efforts to increase the indicated maximum dose of Ferdaps from 80 milligrams per day to 100 milligrams per day. Catalyst submitted a supplementary NDA to the FDA for this change to the maximum daily dose in the second quarter, and October 13th, Catalyst announced the FDA's acceptance of this SNDA for review with an FDA PDUFA action date of June 4th of 2024. While there can be no assurance of approval of this SNDA, barring any significant issues with the application's review, Catalyst anticipates approval of the application on or about June 4th of next year. Currently, there are a number of LEMS patients who are already being treated at a daily dosage of FERDEPs exceeding 80 milligrams after their physician worked with the pharmacy and the insurance providers to justify the higher dose. Other patients on the current indicated maximum dose of 80 milligrams per day and their physicians have expressed a desire to increase the patient's daily dosage above 80 milligrams per day and potentially up to 100 milligrams in order to optimize therapy, And this supplement, if approved, will help those patients. Based on our Type C meeting with the FDA in May of this year and the recent acceptance of the SNDA, we believe that our submission strategy constitutes an acceptable basis for seeking approval of a 100-milligram maximum daily dosage of fur dubs. Regarding our global expansion, we continue to anticipate that DITO4 will submit their NDA for FERDAPS to the Pharmaceuticals and Medical Devices Agency, or PMDA, by the end of this year. Submission of this type typically take about 10 months to review by the PMDA, but there can be no assurance that such a submission will be found approvable within this 10-month period. We previously estimated there are about 1,200 to 1,300 LEMS patients in Japan. Under our license agreement for FERDAPS and upon acceptance of the filing, of this NDA in Japan, Catalyst will gain the right to pursue other territories in the Asia Pacific and South American regions. Catalyst recently announced that the company had received notification by the United States Patent and Trademark Office, or USPTO, that two additional patents covering Ferdaps were allowed. These new patents are for claims associated with the unique and novel, previously unknown, bioavailability of Ferdaps under fasting and fed conditions of dosing. These two new patents with expiry dates out to mid-2032 further strengthen our NAT2 family of patents. We expect these patents to be granted within two months. The preparations are already in motion to include these additional Ferdaps patents in the FDA Orange Book post-grant, bringing the total list of patent count to eight. The addition of this new intellectual property to the Ferdaps product highlights one of our core objectives which is to reinforce and safeguard the sustained commercial viability of Ferdaps, which currently benefits from patent exclusivity protection in the United States until 2037. Next, I would like to discuss our recent in-licensing of Gagamri for the treatment of Duchenne muscular dystrophy, or DMD, from Sanfera for the North American Territory, and also its recent FDA approval on October 26. Agamri is a promising novel steroid with a unique chemical structure that may confer improved long-term safety for this drug. In clinical studies, vomoralone or Agamri demonstrated efficacy with improved muscle function similar to that of prednisone, but with a reduction of steroid-associated side effects over the 48-month duration of the trial that showed benefits in bone health, growth, and behavioral symptoms, offering the potential to address an important unmet medical need. To further characterize the long-term safety of a gamary beyond 48 months, Catalyst is planning to open a registry in the U.S. for DMD patients that are initiated on a gamary. A gamary has received FDA orphan drug exclusivity. DMD is a rare X-linked genetic disorder resulting in progressive muscle degeneration occurring in about 600 male newborns each year. The prevalence is about 11,000 to 13,000 patients, and is gradually increasing as advancements and available treatments are expected to continue to increase the survival of patients with this devastating disease. DMD, the most common form of muscular dystrophy, is a condition that makes the skeletal and heart muscles weaker with time, reducing the lifespan of the affected male patients. The genetic defect lies in the dystrophin gene, and like virtually all X-linked genetic diseases, almost exclusively affects males. Steroids remain the standard of care for DMD patients, and as Jeff pointed out, 75% of DMD patients receive steroid treatment. In addition, approximately 30% of these patients are amenable to one of the approved exon skipping therapies, and a minority of patients would also be eligible for the newly approved gene therapy. However, even the patients treated with exon skipping treatments or gene therapy continue to require corticosteroids at some level, both during treatment and beyond. It is anticipated that Agamri may be a safer and routine long-term clinical use and may lead to earlier initiation of therapy closer to the time of diagnosis and potentially to continue therapy even after loss of ambulation. Overall, Agamri has the potential to be a differentiated treatment for DMD with a desirable profile in comparison to the current standard of care options, addressing an important unmet medical need for DMD patients starting at an early age. The pivotal clinical trial provided data on treatment efficacy and safety associated with Agamri treatment for up to 48 months, which will be augmented by a DMV patient registry in the U.S. for patients that are initiated on Agamri. As previously reported, Catalyst acquired the U.S. rights to Ficopa or Parampanel, which is the first and only approved APA receptor antagonist or inhibitor. Ficopa is approved as an anti-seizure medication for treatment to treat partial onset seizures with or without secondarily generalized seizures in patients with epilepsy who are four years of age or older and in conjunction with other medicines as an add-on therapy to treat primarily generalized tonic-clonic seizures in patients with epilepsy who are 12 years of age or older. While phycopa is a mature epilepsy product, it continues to offer physicians and patients a unique therapeutic option for the management of epilepsy. As I discussed in previous quarterly calls, phycopa's unique mechanisms of action has been a source of great interest to epilepsy researchers that continue to study it for the management of a number of types of epilepsies, including several rare epilepsies of genetic origin. And published papers describe phycopa as the best therapeutic choice for a number of rare epilepsy types. It is for these reasons that we expect the use of FICAPA to continue to grow throughout the remainder of its period of market exclusivity. Catalyst is also continuing to evaluate potential legal options for extending the exclusivity of FICAPA beyond May of 2025. Moving on to our medical information function, Catalyst Neuromuscular Medical Science Liaisons, or MSLs, are continuing to reach out to traditional FERDAPS prescribers and oncology healthcare providers to build relationships and provide education about the importance of testing their patients for LEMS in order to expand the use of Ferdaps. Oncologists that already treat LEMS in their practices have found that patients treated with Ferdaps maintain muscle strength and have an improved quality of life. With the unlicensing of the GAMRI and its planned launch in the first quarter of next year, Catalyst is adding four new MSLs specializing in Duchenne muscular dystrophy to the neuromuscular MSL team. Due to the unique mechanistic features of the GAMRI, it has and continues to be an active area of research that has and will continue to result in an ongoing stream of useful medical information that should be disseminated to doctors so that they can continue to optimize the treatment for their DMD patients. Dissemination of the existing data and publications demonstrating the comparative safety of Agamri relative to its traditional corticosteroids will be the top focus of the neuromuscular MSL team in 2024 and beyond. These efforts should provide clinicians with the information they need to choose the best steroid options for their patients. Catalyst also has plans for advisory board activities to educate DMD treating physicians that were not part of the clinical trials about Agamri. Future updates will be provided as medical information programs are developed and implemented for IGAMRI. Next, Phycopa is a mature product for which extensive published information and real-world data is available. including numerous publications and abstracts. The Phycopa MSL team will continue to disseminate information to epilepsy treaters and will also address any questions that these physicians may have about using Phycopa. Catalyst Phycopa MSL team also attends epilepsy conferences like AES and IEC in order to keep Phycopa in the minds of epilepsy treaters as a potential treatment option for epilepsy patients. As a service to the physician community, Catalyst provides support for the development of continuing medical education, or CME, programs that are part of the formal, ongoing education of healthcare providers. Catalyst has, over the past three years, provided support for three CME programs for various aspects of the diagnosis, treatment, and management of LEMS patients, and we anticipate providing support for more programs, including new programs for a gammering. Over this period of time, thousands of healthcare providers have utilized the CME program's learning modules, and hundreds of them are taking the CME test each quarter in order to be granted CME credit toward the maintenance of their medical licenses. In short, these programs are popular with treaters that use Catalyst products, and based on the CME test-taking frequency, appear to be a valuable part of their ongoing medical education. At this time, I would like to turn the call over to Elisa Grande, our CFO.
spk01: Thanks, Steve. Results from Catalyst's third quarter of 2023 kept us on pace for another year of exceptional financial performance and strong execution. In addition to our outstanding results, I would also like to highlight the excellent job done by the strategy and business development team at Catalyst, which were pivotal to continuing the momentum of our portfolio expansion efforts. As a result, we successfully closed a transaction to acquire the North American commercial rights from Santera during this quarter. This acquisition, in addition to offering an expansion of our portfolio with a promising asset, will also allow us to continue to deliver incremental net positive cash flow for the company and incremental value to our shareholders. While on the topic of Ogambri, I would like to take a moment to discuss some of the key accounting implications and accounting treatment of this transaction. During July 2023, at the time of transaction close, a GAMRI was not yet approved for sale by the U.S. FDA. Consequently, the upfront payment as well as related transaction costs were expensed in the third quarter as in-process research and development, or IPRD. Next, I would like to shift to the regulatory milestone payment. As a result of the FDA approval of a GAMRI on October 26, 2023, We will make a $36 million milestone payment to Sunfera in the fourth quarter of 2023, which will be capitalized on the balance sheet as an intangible asset and amortized over the estimated use for life of 10.5 years or 42 quarters. I would like to reinforce that the approval occurred at the end of October 2023, and as such, amortization expense will be prorated in the fourth quarter of 2023 and then will be consistent going forward. Lastly, in connection with the Montgomery transaction, Catalyst made a strategic equity investment in Santera as part of the acquisition terms. The equity investment has a book value of approximately $13.5 million and will be marked to market value on a quarterly basis using the observable market price for the ticker S-A-N-N of quarter on the sixth Swiss exchange. Now onto Q3 results. Our total revenues for the third quarter of 2023 were $102.7 million, a 79.4% increase when compared to total revenues of $57.2 million for the third quarter of 2022. Product revenue net for the third quarter of 2023 from our lead product furloughs was $66.2 million, a 15.8% increase year over year compared to $57.2 million for the third quarter of 2022. Product revenue net for FERDF was $36.4 million for the third quarter of 2023, which was a 5.2% increase from $34.6 million for the second quarter of 2023. As you might recall, we acquired FICOMPA during January 2023. Net loss before income taxes for third quarter 2023 was $38 million, a $246.2 decrease year-over-year compared to net income before income taxes of $26 million for the third quarter of 2022. We reported gap net loss for the third quarter of 2023 of $30.8 million, or $0.29 per basic undiluted share, a decrease of $235.2 percent year-over-year compared to net income for the third quarter of 2022 of 22.7 million, or 22 cents, earnings per basic and 20 cents per diluted share. The decrease from net income to net loss is largely attributed to the one-time Agamben-related 81.5 million IPR&V expense charged during the third quarter of 2023. Non-GAAP net income for the third quarter of 2023 was $55.9 million, or $0.52 per basic and $0.49 per diluted share, which excludes from GAAP net loss $81.5 million of IPR&D expense, the income tax benefit of $7.3 million, amortization of intangible assets related to our acquisitions of Resurgi and FICOMPA of $8.5 million, Stock-based compensation expense of $3.8 million and depreciation of $81,000. This compares to non-GAAP net income for the third quarter of 2022, $28.6 million or $0.28 per basic and $0.26 per diluted share, which excludes from GAAP net income the income tax provision of $3.3 million, stock-based compensation of $2.1 million, amortization of intangible assets of $518,000 and depreciation of $35,000. The above represents an approximately 95.2% increase of non-GAAP net income year over year. Amortization of intangibles acquired in connection with both the Phi Kappa and the Resurgy products was approximately $8.5 million for the third quarter of 2023. As previously mentioned, beginning in the fourth quarter of 2023 on a quarterly basis, We expect to recognize an additional $857,000 of amortization expense relating to regulatory milestone payments to be made to Suncera due to the timing of approval and thus the recognition of the intangible asset amortization in the fourth quarter of 2023 will be less as it will be prorated. We expect amortization for our acquired licenses and intangible assets to be approximately $9.1 million for the fourth quarter and $9.3 million beginning with the first quarter 2024 and beyond. Our effective tax rate for the third quarter of 2023 on an annualized basis was 23.5% compared to 19.6% for the third quarter of 2022. For 2023, the difference to the statutory federal income tax rate of 21% was primarily driven by state income taxes and anticipated annual permanent differences upset by equity compensation deductions. The effective tax rate is affected by many factors, including the number of stock options exercised in any given period, and is likely to fluctuate in future periods. Cost of sale expenses were approximately $14.2 million in the third quarter of 2023, compared to $9.7 million in the third quarter of 2022, and consisted principally of royalties. As a reminder, royalties of furloughs increased by 3%, when net product sales exceed $100 million in any calendar year. In 2023, this threshold was met during the second quarter, making related royalties trend up for the third quarter. Further, net product sales for the remaining of the year will be subject to the higher royalty rate. Cost of sales for FICOMPA in 2023 is exclusive of amortizations in tangible assets. Research and development expenses were $83.7 million in the third quarter of 2023. This compares to $8.3 million in the third quarter of 2022. As previously mentioned, the driver behind the increase in research and development expenses is relating to the one-time Montgomery IPR&D charge recorded during the third quarter. SG&A expenses for the third quarter of 2023 total $33.6 million compared to $13.7 million in Q3 2022. The increase in SG&A expenses year-over-year is principally due to costs related to SICOMPA, such as commercial expenses under the Transition Services Agreement, selling expenses, and an increase in headcount principally for the sales and marketing force hired during May 2023, but also includes some back office headcount. In addition, there were selling and marketing expenses There were selling and marketing-related expenses incurring the third quarter in anticipation of the Agamben approval and subsequent funds. Finally, we anticipated spending an additional $6 to $7 million in commercial and other expenses related to the Agamben launch preparations during the fourth quarter of 2023. As reported, we ended the quarter with cash and cash equivalents of $121 million. As a reminder, in the fourth quarter of 2023, we will make a 36 million payment to Suncera in connection to the regulatory milestone earned upon the approval of Montgomery by the FDA. We believe our current funds continue to allow us the financial flexibility to fund our existing R&D programs, meet our potential contractual obligations, and support our strategic initiatives, business development, and portfolio expansion efforts, leading to long-term growth and value creation. More detailed information and analysis of our third quarter 2023 financial performance may be found in our quarterly report on Form 10-Q, which was filed with the Securities and Exchange Commission yesterday, November 8th, and can be found on the investor relations page of our website at www.catalystformat.com. And with that, I'll turn the call over to Pat.
spk04: Thanks, Sally. Operator, we can now open the line for questions.
spk05: Thank you. And I'll be conducting your question and answer session. If you'd like to be placed in the question queue, please press star 1 at this time. One moment, please, while we poll for questions. Our first question is coming from June Lee from Truist Securities. Your line is now live.
spk07: Good morning. This is Les on for June. Thank you for taking my questions. First, on the Fair Deps front, can you just talk about any partnership developments on Asia Pacific and Latin America? And then second part to that, what are the two new patents that will be included on the Orange Book? What impact does that have to the ongoing situation with your paragraph four filers? I have a few follow-ups.
spk04: Your first question was about pursuing other territories once we trigger the submission in Japan. Yeah, so we think that based on our preliminary research that there appears to be a great opportunity in China, South Korea, a few smaller markets in the Asia-Pacific region, and also Brazil represents what we think is probably a fairly robust opportunity. So that's where our initial thoughts are. With regard, Steve, you want to take that with regard to the patents?
spk02: Sure. Les, the two new patents that were just allowed have claimed language directed toward the pharmacokinetics of amifampradine in slow and fast metabolizers of amifampradine. They represent a significant addition to our family of patents related to antacetyltransferase metabolism of the drug. And we believe it will significantly strengthen the... that family of patents against a challenge and will improve the ability to enforce our intellectual property.
spk07: Got it. That is helpful. And in regards to FICOMP outperformance, what are some of the driving metrics behind that and how do you see that as the year progresses next year?
spk04: Jeff, do you want to take that?
spk06: Sure. So, Les, what we're looking at is market share is around 14.9% for Phycompa versus the branded anti-seizure medications. We think that our strategy to focus on the existing prescribers of Phycompa, those physicians that have prescribed it over the last year or two years, so just focusing on those physicians and getting those physicians to prescribe for more of their patients than earlier in their treatment protocol. That's been our focus, and we feel that's the biggest contributor to our exceeding our expectations.
spk04: So, Les, let me add that as a fairly mature product, we continue to expect that we can grow it by single-digit, high single-digit from year to year, so I hope that helps answer your question.
spk07: It does. Thank you, Pat. I guess last one for me then on the acquisition front potentiality there. It sounds like you're in advanced due diligence process. It appears to be in an epilepsy asset. Maybe give some more color around that. If it is, how would that fit into the current sales force with ICOMPA? And is a potential acquisition essentially covered by the current cash balance? Thank you.
spk04: Yeah. And so, you know, we've made it clear that from a strategic plan that our emphasis on our next acquisition, really, we'd like it something to be compatible with our epilepsy franchise. And we think it's a It's a growing opportunity, and clearly we've made that point. I would not say that there's anything imminent. We're in deep diligence on a couple of opportunities. We want to be careful about doing too many acquisitions too quickly. We want to make sure that we integrate and we execute with each of these opportunities that we bring in. most importantly. And certainly with, as stated, our nine-month cash position of $121 million, which continues to grow quarter by quarter, we think we're in a fairly good position to do another tuck-in or two. But I would not say that anything is imminent today. We hope over the next couple of quarters that we can announce another acquisition.
spk07: Great. Thank you, guys. Congrats on the performance.
spk05: Thank you. Thank you. Next question today is coming from Charles Duncan from Cancer for Children. Your line is now live.
spk09: Hey, good morning, Pat and team. Congratulations on a great third quarter. And, Pat, you know, frankly, congratulations and good luck with your career milestone and transition. Thank you, Charles. Yeah, so thanks for taking our questions. I had a couple of questions on the mora loan or a GAMRI and then one on the SNDA for DAPs. For the mora loan, I guess I'm wondering if Steve or even Jeff could speak to the current market dynamics, I guess, any impact of the recent Embark results on, you know, what you think is going to be the demand for a GAMRI, and what do you anticipate in terms of the pace of adoption? Will there be switching of patients from current standard of care, or will it be primarily targeting new patients? Thank you.
spk04: Yeah, thanks, Charles, for the question. I'll pass this to Steve. Steve, you want to pick this up?
spk02: Okay. Well, let me answer your first question about the Embark results, and it really speaks to a more general question regarding overall gene therapies and exon skipping therapies. The bottom line is that with the use of those therapies, patients still have a need for taking some kind of corticosteroid both during the treatment with those alternate treatments as well as afterwards. There's variability in how well the patients respond to therapy. And the Embark results, I don't want to comment on another company's products, so there's not much I can say about those. But the bottom line is that we anticipate that there will continue to be healthy demand for steroid treatments for DMV patients. And now I apologize. Can you repeat the other question, Charles?
spk04: Yes, Steve. I'll pass that to Jeff. The question was about switching, patient switching and some of the dynamics.
spk02: Okay.
spk06: Yeah, hi, Charles. Here are the market dynamics for corticosteroids for DMD right now. As we mentioned, 11,000 to 13,000 patients living with DMD in the U.S. Of those 11,000 to 13,000, about 70% are on steroids. Now, when you look at the market share breakdown there, it's about a 60% prednisone market share and about a 35 to 40% are on Enflaza. And when you look at the potential patients for a Gamre, they will be the switch patients, primarily from Enflaza, but also, based on feedback that we're hearing, are some of these patients that are on prednisone. You will see some patients that are naive to steroids, but that'll be a smaller percentage, and over time that may happen. But I think for the initial launch, the patients that are currently on steroids will be looking to switch over.
spk09: Okay, that's helpful. And then a quick question on the SN-AEA for the 100 milligram dosage of Ferdvabs. Probably hard to speculate now, but I am going to ask, what do you think the key questions will be from the agency? Will it be around safety or efficacy?
spk02: Steve, we haven't done that yet. Sure. Well, that's an interesting question, Charles. The short answer to your question is, if they have any further questions beyond what we've already submitted them, and we think that their questions will be relatively sparse based on our type C meeting. But with regard to efficacy, they would want to know, is the drug efficacious at the 100 milligram dose? And we have plenty of data that was submitted in the SNDA that demonstrates efficacy at the 100 milligram dose. The second thing that they would want to know is, will the drug be safe at a higher dose? That's 20% higher than the currently labeled dose of 80 milligrams per day. And again, we submitted a significant body of evidence that showed that there are no safety concerns at a dose of 100 milligrams per day. And as a result of that, it's unlikely they'll have any really hard questions about that, but you can never predict the future. I also want to point something out. Resurgi, which was previously approved by the FDA, was approved for a 100-milligram dose. And so as a result, some of that data is actually in our SMDA, and it's for that reason that we also believe that the FDA will be receptive to a 100-milligram dosage application.
spk09: That's helpful.
spk04: To put a fine point on that, and that label was a pediatric label?
spk02: Yes.
spk09: Okay, got it. That highlights safety. Last quick question. Do you plan to have a presence at the upcoming AES meeting in Orlando? I believe it's early December. Thanks.
spk06: Jeff? Hi, Charles. We will definitely be there. We are going to have a huge presence with our MedAffairs team as well as our commercial team.
spk09: Okay. Thanks for taking the questions. Congrats on the course.
spk05: Thank you. Thank you. Next question is coming from Joe Catanzaro from Piper Sandler. Your line is now live.
spk03: Hey, guys. Thanks for taking my questions. Maybe two quick ones for me. First one, maybe similar to an earlier question, but wanted to ask about the strategy to price Agamri at a slight discount to Enflaza. Just wanted to see if you could elaborate around some of the reasons to do that, the potential benefits you see from that, and whether you think that could actually drive more active switching from Inflaza onto Agamri. That's my first one, and I have one follow-up. Thanks.
spk04: Sure. Jeff, do you want to speak to some of the work that was done to help us arrive at our pricing?
spk06: Sure. So, Joe, we'll provide a lot more details as we get closer to launch, but specific to the pricing and the considerations that we took, we did significant payer outreach as well as you know, speaking with advocacy and patients, and then also, you know, like KOLs. So that helped us form our decision to price it very similar at a slight discount to Inflaza. So that's the specifics behind that. But did I answer your question?
spk03: Yeah, that's helpful. I guess I was primarily interested on whether, you know, you could see that as a key factor in the sort of switching dynamics.
spk06: You know, we do anticipate at that price point or a slight discount that there's potential benefits from a payer landscape and not necessitating a further step through INFLASA. And that was all part of the research, too.
spk03: Okay, got it. My second question I wanted to ask around the two key pillars you mentioned, Pat, and the potential to expand the geographic footprints of existing products. I know you mentioned the opportunity for FERDAPs in Asia Pacific and Latin America, but wondering, based on license agreements, if there are any potential opportunities you might see for FICOMPA and IGAMRI outside of the U.S.
spk04: Thanks. Not for FICOMPA, Joe, but for IGAMRI, our license does allow some market expansion I can't be specific at the moment about that, but there are some opportunities. Santera, we know, is going to market Gamre in the five key European markets. And so there are opportunities outside of that for us. They do have a partner already in China. So we... We have a good working relationship with Santerra. In fact, next week they'll be here for a joint development committee meeting, and those are topics that are right on the agenda.
spk03: Okay, great. Appreciate you guys taking my questions. Thanks again.
spk05: Thanks, Joe. Thank you. Next question is given from Scott Henry from Roth Capital Partners. Your line is now live.
spk08: Thank you, and good morning. A core competency of Catalyst has really been the access program. Excellent job with Catalyst pathways. The question is when you compare the LEMS market to the Duchenne's market, how similar do you think that will be? What are the differences when bringing about access between those markets? It seems a little more competitive than the Duchenne's market. Just any color you would have on that. Thank you.
spk04: Yeah, great question, Scott. I'll let Jeff take this.
spk06: Scott, I mean, the biggest difference between the two therapeutic areas, when you look at DMD, not only the competitive landscape that you mentioned, but really it's Medicaid patients. It's about 50% or so Medicaid patients. And then the balance for the most part is commercial. Whereas the LEM side, you had a significant part of those, the population is Medicare. You have 45% with Medicare and 35% is commercial. So that's the biggest part there. But the biggest thing for us is that we want to ensure that there's access for all patients that physicians and families think the patient should be on a gamma. We want to make sure that there's there's access for these patients. So we are committed to ensuring that all those patients have an average copay of $2 per month. So, you know, we've done a lot of research, we've done a lot of strategy planning, and that's what our focus will be when we launch.
spk08: For that color. And then final question, and I don't know how much you really want to talk about this now, but when you compare Implaza to Agamri, You know, are there any key differences that will make up your marketing message as far as to promote a switch there? Just trying to think about the key levers that one would compare the two on.
spk04: You know, Scott, we continue to do a lot of work. We have, you know, primary research and secondary market research, and we're not quite ready to open the kimono entirely. with regard to marketing strategies and how we'll position ourselves against other programs. Jeff, you wanna add to that?
spk06: Sure, so Scott, the thing about the DMD space is it's a very defined market. And there are about 90 plus, I think we've calculated now 103, we've profiled centers of excellence or accounts primarily, and about 250 prescribers. key prescribers for these boys living with Duchenne. And, you know, the data has been out there for a long time, and all the stakeholders are pretty much aware of this data and some of the benefits of a GAMRI versus what's on the market. So, you know, we stand behind that data, and it'll be a collaboration really between commercial and MedAffairs to ensure that that data is received by the appropriate stakeholders. But that's been our approach. And like Pat mentioned, we'll share more specifics about the commercialization here in the next month or two.
spk08: Okay, great. That's helpful. I completely understand. And congratulations again, Pat. Great career, but I think you've got a couple more chapters to write. But it's been great to watch.
spk05: Thanks, Scott.
spk04: Thank you.
spk05: Thank you. We've reached the end of our question and answer session. I'd like to turn the floor back over to Pat for any further closing comments.
spk04: Thank you. In conclusion, our dedication to pioneering solutions for rare diseases remains unwavering. As we approach 2024 with eagerness, we are well poised to leverage our strengths, maximize the potential of our promising product portfolio, and enhance the lives of patients grappling with rare diseases. I want to thank you for your steadfast support over the years. And here's to a future brimming with boundless potential under the stewardship of Rich Daly. Thank you.
spk05: Thank you. That does conclude today's teleconference and webcast. You may disconnect your line at this time and have a wonderful day. We thank you for your participation today.
Disclaimer